Primary Myelofibrosis: all 431 studies

Page 2 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.

• Managed Access Programs for INC424, RuxolitinibAvailableNCT04745637
• Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisRecruitingNCT04655118Phase 2
• KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFRecruitingNCT04640532Phase 1/2
• Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisRecruitingNCT04370301Phase 2
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
• A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingNCT04176198Phase 1/2
• Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantRecruitingNCT03964506Early Phase 1
• Individual Patient Compassionate Use of FedratinibAvailableNCT03723148
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentRecruitingNCT03662126Phase 2/3
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
• Selumetinib and Azacitidine in High Risk Chronic Blood CancersRecruitingNCT03326310Phase 1
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With MyelofibrosisRecruitingNCT02934477
• Myeloproliferative Neoplastic Diseases Observatory From BrestRecruitingNCT02897297
• Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
• Quantitative MRI for MyelofibrosisRecruitingNCT01973881
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)CompletedNCT05223920Phase 2Results posted
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2Results posted
• Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisTerminatedNCT04854096Phase 2Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsActive, not recruitingNCT04717414Phase 3Results posted
• Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia MyelofibrosisCompletedNCT04676529Phase 1/2Results posted
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active, not recruitingNCT04603495Phase 3Results posted
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedNCT04551066Phase 3Results posted
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedNCT04551053Phase 3Results posted
• Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedNCT04543279Phase 2Results posted
• Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisCompletedNCT04472598Phase 3Results posted
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell TransplantationCompletedNCT04339101Phase 2Results posted
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationCompletedNCT04281498Phase 2Results posted
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3Results posted
• Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis PatientsTerminatedNCT04097821Phase 1/2Results posted
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsTerminatedNCT03878199Phase 1/2Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and MyelofibrosisTerminatedNCT03718143Phase 2Results posted
• Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 InhibitorsTerminatedNCT03627403Phase 2Results posted
• CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic TransplantActive, not recruitingNCT03560752Phase 1Results posted
• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' ExpressionCompletedNCT03480360Phase 3Results posted
• Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.CompletedNCT03427866Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Allogeneic Stem Cell Transplantation for Multiple Myeloma and MyelofibrosisTerminatedNCT03303950Phase 2Results posted
• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT03289910Phase 2Results posted
• A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With MyelofibrosisCompletedNCT03222609Phase 2Results posted
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaTerminatedNCT03195010Phase 2Results posted
• A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion DependenceCompletedNCT03194542Phase 2Results posted
• A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedNCT03144687Phase 2Results posted
• Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)CompletedNCT03136185Phase 1/2Results posted
• PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsCompletedNCT03065400Phase 2Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
• Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisCompletedNCT02784496Phase 2Results posted
• Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and AnemiaTerminatedNCT02730884Phase 2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesTerminatedNCT02712905Phase 1/2Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.TerminatedNCT02598297Phase 3Results posted
• Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic LeukemiaStatus unknownNCT02530619Not applicableResults posted
• Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2Results posted
• Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantActive, not recruitingNCT02506933Phase 2Results posted
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) InhibitorCompletedNCT02426086Phase 2Results posted
• Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisTerminatedNCT02421354Phase 2Results posted
• P1101 in Treating Patients With MyelofibrosisTerminatedNCT02370329Phase 2Results posted
• Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)CompletedNCT02268253Phase 1/2Results posted
• Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedNCT02267278Phase 2Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibTerminatedNCT02226172Phase 2Results posted
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedNCT02158858Phase 1/2Results posted
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2Results posted
• Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3Results posted
• LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisCompletedNCT02098161Phase 2Results posted
• A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)TerminatedNCT02091752Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• Post Transplant Cyclophosphamide (Cytoxan) for GvHD ProphylaxisCompletedNCT02065154Phase 2Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• A Phase 2 Study of RO7490677 In Participants With MyelofibrosisCompletedNCT01981850Phase 2Results posted
• Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedNCT01969838Phase 3Results posted
• Myeloproliferative Neoplasms: an In-depth Case-control StudyCompletedNCT01831635Results posted
• Ruxolitinib Prior to Transplant in Patients With MyelofibrosisTerminatedNCT01790295Phase 2Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• Pacritinib Versus Best Available Therapy to Treat MyelofibrosisTerminatedNCT01773187Phase 3Results posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Pegylated Interferon Alpha-2b in Early Primary MyelofibrosisTerminatedNCT01758588Phase 2Results posted
• Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With MyelofibrosisCompletedNCT01732445Phase 2Results posted
• Imetelstat Sodium in Treating Participants With Primary or Secondary MyelofibrosisCompletedNCT01731951Phase 2Results posted
• Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaCompletedNCT01712308Phase 2Results posted
• Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)CompletedNCT01693601Phase 1/2Results posted
• HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETTerminatedNCT01668173Phase 2Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.CompletedNCT01493414Phase 3Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyCompletedNCT01428635Phase 2/3Results posted

← Primary Myelofibrosis overview